Driven By The Urgency Of Cancer Patients Who Need Effective Therapies

Our mission is to develop best-in-class and first-in-class precision medicines directed to specific oncogenic vulnerabilities in patients with limited treatment options.

A Focused Pipeline Portfolio

We have assembled a team with deep expertise in medicinal chemistry, cancer genetics and translational biology to accelerate the development and delivery of kinase inhibitor-based therapies.

An Experienced Team of Precision Oncology Leaders

Latest News

Kinnate Biopharma Appoints Dr. Richard Williams as Chief Medical Officer

Precision Oncology News: Kinnate Exiting Stealth Mode With Plans to Move Lead RAF Inhibitor Into Clinical Trials Next Year

Kinnate Biopharma Appoints Nima Farzan as Chief Executive Officer

Kinnate Biopharma Closes $74.5M Series B Financing

Fount Therapeutics Secures $22M Series A Financing

Help Us Improve Lives

Have A Question?